1. Parry CH. Enlargement of the thyroid gland in connection with enlargement or palpitation of the heart. Collections from the unpublished papers of the late Caleb Hillier Parry 1825: 111-125
2. Graves RJ. Newly observed affections of the thyroid gland in women. London Med & Surg J 1835; 7: 516-517
3. Von Basedow CA. Exophthalmos durch Hypertrophie des Zellgewebes in der Augenhöhle. Wochenschr f. Gesamt Heilkunde 1840: 197-220
4. Zondek H. Das Myxödemherz. Münch Med Wschr. 1918; 65: 1180- 1183
5. Dillmann WH. Thyroid hormones and the heart: basic mechanistic and clinical issues. Thyroid Today 1996; 19 (1)
6. Ladenson PW, Kieffer JD, Farwell AP, Ridgway EC. Modulation of myocardial L-triiodothyronine receptors in normal, hypothyroid and hyperthyroid rats. Metabolism 1986; 35: 5-12
7. Sap J, Munoz A, Damm K, et al. The c-erb-A protein is a high affinity receptor for thyroid hormone. Nature 1986; 324: 653-640
8. Weinberger C, Thompson CC, Ong ES, et al. The c-erb-A gene encodes a thyroid hormone receptor. Nature 1986; 324: 641-646
9. Schwartz K, Lecarpentier Y, Martin JL, et al. Myosin isoenzymic distribution correlates with speed of myocardial contraction. J Mol Cell Cardiol 1981; 13: 1071-1075
10. Lompre AM, Nadal-Ginard B, Mahdavi V. Expression of the cardiac ventricular a- and ß-myosin heavy chain genes is developmentally and hormonally regulated. J Biol Chem 1984; 259: 6437-6446
11. Izumo S, Mahdavi V. Thyroid hormone receptor a isoforms generated by alternative splicing differentially activate HC gen transcription. Nature 1988; 334: 539-542
12. Ridgway RC. Molecular biology of thyroid hormone action: TSH subunit and cardiac myosin ATPase genes. Thyroid Today 1989; 12 (3)
13. Ladenson PW, Sherman SI, Baughman KL, Ray PE, Feldman AM. Reversible alterations in myocardial gene expression in a young man with dilated cardiomyopathy and hypothyroidism. Proc Natl Acad Sci USA 1992; 89: 5251- 5255
14. Suko J. The calcium pump of cardiac sarcoplasmic reticulum. Functional alterations at different levels of thyroid state in rabbits. J Physiol 1973; 228: 563-581
15. Rohrer D, Dillmann WH. Thyroid hormone markedly increases the mRNA coding for sarcoplasmic reticulum Ca++ATPase in the rat heart. J Biol Chem 1988; 263: 6941-6944
16. Rohrer DK, Hartong R, Dillmann WH. Influence of thyroid hormone and retinoic acid on slow sarcoplasmic reticulum Ca++ATPase and myosin heavy chain a gene expression in cardiac myocytes: delineation of cis-active DNA elements that confer responsiveness to thyroid hormone but not to retinoic acid. J Biol Chem 1991; 266: 8638-8646
17. Segal J. Acute effects of thyroid hormone on the heart: an extranuclear increase in sugar uptake. J Mol Cell Cardiol 1989; 21: 323-334
18. Bottinelli R, Canepari M, Capelli V, Reggiani C. Maximum speed of shortening and ATPase activity in atrial and ventricular myocardia of hyperthyroid rats. Am J Physiol 1995; 269: C785-C790
19. Mylotte KM, Cody V, Davis PJ, et al. Milrinone and thyroid hormone stimulate myocardial membrane Ca++ATPase activity and share structural homologies. Proc Natl Acad Sci USA 1985; 82: 7974-7978
20. Segal J: Calcium is the first messenger for the action of thyroid hormone at the level of the plasma membrane: first evidence for an acute effect of thyroid hormone on calcium uptake in the heart. Endocrinology 1990; 126: 2693- 2702
21. Dudley SC, Baumgarten CM. Bursting of cardiac sodium channels after acute exposure to 3,5,3'-triiodo-L-thyronine. Circ Res 1993; 73: 301-313
22. Orlowski J, Lingrel JB. Thyroid and glucocorticoid hormones regulate the expression of multiple Na,K-ATPase genes in cultured neonatal rat cardiac myoctes. J Biol Chem 1990; 265: 3462-3470
23. Kim D, Smith TW, Marsh JD. Effect of thyroid hormone on slow calcium function in cultured chick ventricular cells. J Clin Invest 1987; 80: 88-94
24. Gøtzsche LBH. L-triiodothyronine acutely increases Ca2-uptake in the isolated, perfused rat heart. Changes in L-type Ca2-channels and ß- receptors during short- and long-term hyper- and hypothyroidism. Eur J Endocrinol 1994; 130: 171-179
25. Bilezikian JP, Loeb JN. The influence of hyperthyroidism and hypothyroidism on a and ß-adrenergic receptor systems and adrenergic responsiveness. Endocr Rev 1983; 414: 378-387
26. Stiles GL, Lefkowitz RJ. Thyroid hormone modulation of agonist-ß- adrenergic receptor interactions in the rat heart. Life Sci 1981; 28: 2: 2529- 2536
27. Hammond HK, White FC, Buxton ILO, et al. Increased myocardial ß- receptors and adrenergic responses in hyperthyroid pigs. Am J Physiol 1987; 252: H283-H290
28. Martin WH, Spina RJ, Korte E. Effect of hyperthyroidism of short duration on cardiac sensitivity to ß-adrenergic stimulation. J Am Coll Cardiol 1992; 19: 1185-1191
29. Ransnas L, Hammond HK, Insel PA. Increased Gs in myocardial membranes from hyperthyroid pigs. Clin Res 1988; 36: 552A
30. Brodde OE. ß1- and ß2-adrenoreceptors in the human heart: properties, function, and alterations in chronic heart failure. Pharmacol Rev 1991; 43: 203-242
31. Muntz KH. Autoradiographic characterization of ß-adrenergic receptor subtype in the canine conduction system. Circ Res 1992; 71: 51-57
32. Bahouth SW. Thyroid hormones transcriptionally regulate the ß1- adrenergic receptor gene in cultured ventricular myocytes. J Biol Chem 1991; 266: 15863-15869
33. Ojamaa K, Balkman C, Klein I. Acute effects of T3 on vascular smooth muscle cells. Ann Thorac Surg 1993; 56: 561-567
34. Theilen EO, Wilson WR. Hemodynamic effects of peripheral vasoconstriction in normal and thyrotoxic subjects. J Appl Physiol 1967; 22: 207-210
35. Goldman S, Olajos M, Morkin E. Control of cardiac output in thyrotoxic calves: evaluation of changes in the systemic circulation. J Clin Invest 1984; 73: 358-365
36. Gay R, Lee RW, Appleton C, et al. Control of cardiac function and venous return in thyrotoxic calves. Am J physiol 1987; 252: H467-H473
37. Gay RG, Raya TE, Lancaster LD, et al. Effects of thyroid state on venous compliance and left ventricular performance in rats. Am J Physiol 1988; 254: H81-H88
38. Klein I, Hong C. Effects of thyroid hormone on cardiac size and myosin content of the heterotopically transplanted rat heart. J Clin Invest 1986; 77: 1694-1698
39. Klein I, Ojamaa K, Samarel AM, Welikson R, Hong C. Hemodynamic regulation of myosin heavy chain gene expression: studies in the transplanted rat heart. J Clin Invest 1992; 89: 68-73
40. Ojamaa K, Samarel AM, Kupfer JM, Hong C, Klein I. Thyroid hormone effects on cardiac gene expression independent of cardiac growth and protein synthesis. Am J Physiol 1992; 263: E534-E540
41. Ojamaa K, Klemperer JD, MacGilvray SS, Klein I, Samarel A. Thyroid hormone and hemodynamic regulation of ß-myosin heavy chain promoter in the heart. Endocrinology 1996: 137: 802-808
42. Parving HH, Hansen JM, Nielsen SL, et al. Mechanisms of edema formation in myxedema - increased protein extravasation and relatively slow lymphatic drainage. N Engl J Med 1979; 301: 460-465
43. Klein I, Ojamaa K. Thyroid hormone and blood pressure regulation. In Laragh JH, Brenner BM (eds.): Hypertension: pathophysiology, diagnosis and treatment. Raven Press, New York, 1994
44. Streeten DHP, Anderson GH, Howland T, Chiang R, Smulyan H. Effects of thyroid function on blood pressure. Hypertension 1988; 11: 78-83
45. Bing RF, Briggs RSJ, Burden AC, et al. Reversible hypertension and hypothyroidism. Clin Endocrinol 1980; 13: 339-342
46. Ladenson PW, Block KD, Seidman JG. Modulation of atrial natriuretic factor by thyroid hormone: messenger ribonucleic acid and peptide levels in hypothyroid, euthyroid, and hyperthyroid rat atria and ventricles. Endocrinology 1988; 123: 652-659
47. Drvota V, Janson A, Norman C, et al. Evidence for the presence of functional thyrotropin receptor in cardiac muscle. BBRC 1995; 211: 426-431
48. Koshiyama H, Sellitti DF, Akamizu T, et al. Cardiomyopathy associated with Graves' disease. Clin Endocrinol 1996; 45: 111-116
49. Otto E, Förster G, Kuhlemann K, Hansen C, Kahaly G. TSH receptor in endocrine autoimmunity. Clin Exp Rheumatol 1996; 14: 77-84
50. Polikar R, Burger AG, Scherrer U, Nicod P. The thyroid and the heart. Circulation 1993; 87: 1435-1441
51. Mohr-Kahaly S, Kahaly G, Meyer J. Cardiovascular involvement in thyroid disease. Z Kardiol 1996; 85: 219-231
52. Aronow WS. The heart and thyroid disease. Clinics in Geriatric Medicine 1995; 11: 219-229
53. Nordyke RA, Gilbert FI, Harada AS. 1988 Graves' disease: influence of age on clinical findings. Arch Intern Med 148: 626-631
54. Davis PJ, Davis FB. Hypothyroidism in patients over the age of 60 years. Medicine 1974; 53: 161-181
55. Trivalle C, Doucet J, Chassagne P, et al. 1996 Differences in the signs and symptoms of hyperthyroidism in older and younger patients. J Am Geriatr Soc 44: 50-53
56. Kahaly G, Mohr-Kahaly S, Beyer J, Meyer J. Left ventricular function analyzed by Doppler and echocardiographic methods in short-term hypothyroidism. Am J Cardiol 1995; 75: 645-648
57. Crowley WF, Ridgway EC, Bough EW, et al. Non-invasive evaluation of cardiac function in hypothyroid-ism: response to gradual thyroxine replacement. N Engl J Med 1977; 296: 1-6
58. Valente M, De Santo C, de Martino Rosaroll P, et al. The direct effect of the thyroid hormone on cardiac chronotropism. Arch Int Physiol Biochem 1988; 97: 431-440
59. Freedberg AS, Papp JG, Vaugham Williams EM. The effect of altered thyroid state on atrial intracellular potentials. J Physiol 1970; 207: 357-369
60. Johnson PN, Freedberg AS, Marshall JM. Action of thyroid hormone on the transmembrane potentials from sinoatrial node cells and atrial muscle cells in isolated atria of rabbits. Cardiology 1973; 58: 273-289
61. Arnsdorf MF, Childers RW. Atrial electrophysiology in experimental hyperthyroidism in rabbits. Circ Res 1970; 26: 575-581
62. Kim D, Smith TW. Effect of thyroid hormone on sodium pump sites, sodium content, and contractile response to cardiac glycosides in cultured chick ventricular cells. J Clin Invest 1984; 74: 1481-1488
63. Olshausen K, Bischoff S, Kahaly G, et al. Cardiac arryhthmias and heart rate in hyperthyroidism. Am J Cardiol 1989; 63: 930-933
64. Polikar R, Feld GK, Dittrich HC, Smith J, Nicod P. effect of thyroid replacement therapy on the frequency of benign atrial and ventricular arrhythmias. J Am Coll Cardiol 1989; 14: 999-1002
65. Roti E, Montermini M, Roti S, et al. The effect of Diltiazem, a calcium channel-blocking drug, on cardiac rate and rhythm in hyperthyroid patients. Arch Intern Med 1988; 148: 1919-1921
66. Northcote RJ, MacFarlane P, Kesson CM, Ballantyne D. Continuous 24-hour electrocardiography in thyrotoxicosis before and after treatment. Am Heart J 1986; 112: 339-344
67. Venkatesh N, Lynch JJ, Uprichard ACG, et al. Hypothyroidism renders protection against lethal ventricular arrhythmias in a conscious canine model of sudden death. J Cardiovasc Pharmacol 1991; 18: 703-710
68. Pies M, Hellerman J, Treese N, et al. Cardiovascular parameters in transitory hypothyroidism. Z Kardiol 1995; 84: 668-674
69. Kahaly G, Nieswandt J, Mohr-Kahaly S. Cardiac risks of hyperthyroidism in the elderly. Thyroid 1998 (in press)
70. Ronnov-Jensen V, Kirkegaard C. Hyperthyroidism-a disease of old age? Br Med J 1973; 1: 41-43
71. Agner T, Almdal T, Thorsteinsson B, Agner E. A reevaluation of atrial fibrillation in thyrotoxicosis. Dan Med Bull 1984; 31: 157-159
72. Mohacsi A, Worum F, Lorincz I, Nagy E, Leövey A. Incidence of rhythm disorders in hyperthyrosis with special respect of old age form. Acta Medica Hungarica 1990; 47: 21-29
73. Iwasaki T, Naka M, Hiramatsu K et al. Echocardiographic studies on the relationship between atrial fibrillation and atrial enlargement in patients with hyperthyroidism of Graves' disease. Cardiology 1989; 76: 10-17
74. Sawin CT, Geller A, Wolf PA, et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med 1994; 331: 1249-1251
75. Nakazawa K, Sakurai K, Hamada N, Momotani N, Ito K. Management of atrial fibrillation in the post-thyrotoxic state. Am J Med 1982; 72: 903-906
76. Ladenson PW. Editorial: Thyrotoxicosis and the Heart: something old and something new. J Clin Endocrinol Metab 1993; 77: 332-333
77. Parker JLW, Lawson DH. Death from thyrotoxicosis. Lancet 1973; ii: 894- 896
78. Staffurth JS, Gibberd JS, Tang FS. Arterial embolism in thyrotoxicosis with atrial fibrillation. Brit Med J 1977; ii: 688-690
79. Bar-Sela S, Ehrenfeld M, Eliakim M. Arterial embolism in thyrotoxicosis with atrial fibrillation. Arch Intern Med 1981; 141: 1191-1192
80. Petersen P, Hansen JM. Stroke in thyrotoxicosis with atrial fibrillation. Stroke 1988; 19: 15-18
81. Presti CF, Hart RG. 1989 Thyrotoxicosis, atrial fibrillation, and embolism, revisited. Am Heart J 117: 976-977
82. Steinberg AD. Myxedema and coronary artery disease-A comparative autopsy study. Ann Intern Med 1968; 68: 338-344
83. Kinlaw WB. Atherosclerosis and the thyroid. Thyroid today 1991; 14 (2)
84. Keating FR, Parkin TW, Selby JB, Dickenson LS. Treatment of heart diseases associated with myxedema. Prog Cardiovasc Dis 1960; 3: 364-381
85. Perk M, O'Neill BJ. The effect of thyroid hormone therapy on angiographic coronary artery disease progression. Can J Cardiol 1997; 13: 273-276
86. Ladenson PW, Levin AA, Ridgway EC, Daniels GH. Complications of surgery in hypothyroid patients. Am J Med 1984; 77: 261-266
87. Sherman SI, Ladenson PW. Percutaneous transluminal angioplasty in hypothyroidism. Am J Med 1991; 90: 367-370
88. Banovac K, Papic M, Bilkser MS, Zakarija M, McKenzie M. Evidence of hyperthyroidism in apparently euthyroid patients treated with levothyroxine. Arch Intern Med 1989; 149: 809-812
89. Tseng KH, Walfish PG, Persaud JA, Gilbert BW. Concurrent aortic and mitral valve echocardiography permits measurement of systolic time intervals as an index of peripheral tissue thyroid function status. J Clin Endocrinol Metab 1989; 69: 633-638
90. Biondi B, Fazio S, Carella C, et al. Cardiac effects of long term thyrotropin-suppressive therapy with levothyroxine. J Clin Endocrinol Metab 1993; 77: 334-338
91. Fazio S, Biondi B, Carella C, et al. Diastolic dysfunction in patients on thyroid-stimulating hormone suppressive therapy with levothyroxine: beneficial effect of ß-blockade. J Clin Endocrinol Metab 1995:2222- 2226
92. Biondi B, Fazio S, Cuocolo A, et al. Impaired cardiac reserve and exercise capacity in patients receiving long-term thyrotropin suppressive therapy with levothyroxine. J Clin Endocrinol Metab 1996; 81:4224-4228
93. Biondi B, Fazio S, Carella C, et al. Control of adrenergic overactivity by beta-blockade improves quality of life in patients on long-term suppressive therapy with levothyroxine. J Clin Endocrinol Metab 1994;78:1028-1033
94. Ching GW, Franklyn JA, Stallard TJ, Daykin J, Sheppard MC, Gammage MD. Cardiac hypertrophy as a result of long-term thyroxine therapy and thyrotoxicosis. Heart 1996; 75:363-368
95. Shapiro LE, Sievert R, Ong L, et al. Minimal cardiac effects in asymptomatic athyreotic patients chronically treated with thyrotropin- suppressive doses of L-thyroxine. J Clin Endocrinol Metab 1997; 82:
2592-2595
96. Ridgway EC, Cooper DS, Walker H, Rodbard D, Maloof FM. Peripheral responses to thyroid hormone before and after L-thyroxine therapy in patients with subclinical hypothyroidism. J Clin Endocrinol Metab 1981; 53: 1238-1242
97. Cooper DS, Halpern R, Wood LC, Levin AA, Ridgway EC. L-thyroxine therapy in subclinical hypothyroidism: a double-blind, placebo-controlled trial. Ann Int Med 1984; 101: 18-24
98. Forfar JC, Muir AL, Sawers SA, Toft AD. Abnormal left ventricular function in hyperthyroidism. Evidence for a possible reversible cardiomyopathy. N Engl J Med 1982; 307: 1165-1170
99. Forfar JC, Muir AL, Toft AD. Left ventricular function in hypothyroidism. Responses to exercise and beta adrenoceptor blockade. Br Heart J 1982; 48: 278-284
100. Kahaly G, Hellermann J, Mohr-Kahaly S, Treese N. 1996 Impaired cardiopulmonary exercise capacity in hyperthyroidism. Chest 109: 57-61
101. Hellermann J, Kahaly G. Cardiopulmonary involvement in thyroid disease. Pneumologie 1996;50:375-380
102. Mohr-Kahaly, Wagner S, Nieswandt J, Hommel G, Kahaly G. Dynamic stress- echocardiography and cardiopulmonary exercise testing in hyperthyroidism. Thyroid 1996; 6: S28, Abstract 55
103. Wassermann K. Diagnosing cardiovascular and lung pathophysiology from exercise gas exchange. Chest 1997; 112: 1091-1101
104. Morkin E, Pennock GD, Raya TE, Bahl JJ, Goldman S. Studies on the use of thyroid hormone and a thyroid hormone analogue in the treatment of congestive heart failure. Ann Thorac Surg 1993; 56: 54-60
105. Moruzzi P, Doria E, Agostini PG, Capacchione V, Sganzerla P. Usefulness of L-Thyroxine to improve cardiac and exercise performance in idiopathic dilated cardiomyopathy. Am J Cardiol 1994; 73: 374-378
106. Moruzzi P, Doria E, Agostini PG. Medium-term effectiveness of L- Thyroxine treatment in idiopathic dilated cardiomyopathy. Am J Med 1996; 101: 461-467
107. Clark RE. Cardiopulmonary bypass and thyroid hormone metabolism. Ann Thorac Surg 1993; 56: 35-42
108. Novitzky D, Cooper DKC, Barton CI, et al. Triiodothyronine as an inotropic agent after open heart surgery. J Thorac Cardiovasc Surg 1989; 98: 972-977
109. Novitzky D, Cooper DKC, Chaffin JS, et al. Improved cardiac allograft function following triiodothyronine therapy to both donor and recipent. Transplantation 1990; 49: 311-316
110. Klemperer JD, Klein I, Gomez M, et al. Thyroid hormone treatment after coronary-artery bypass surgery. N Engl J Med 1995; 333: 1522-1527
111. Bennett-Guerrero E, Jiminez JL, White WD, et al. Cardiovascular effects of intravenous triiodothyronine in patients undergoing coronary artery bypass graft surgery: a randomized, double-blind, placebo-controlled trial. JAMA 1996; 275: 687-692
112. Davies MJ, Moore BP, Braimbridge MV. The floppy mitral valve. Study of incidence, pathology, and complications in surgical, necropsy, and forensic material. Br Heart J 1978; 40: 468-481
113. Hansen C, Otto E, Kuhlemann K, Förster G, Kahaly G. Glycosaminoglycans in autoimmunity. Clin Exp Rheumatol 1996; 14: 59-68
114. Hansen C, Fraiture B, Rouhi R, Otto E, Förster G, Kahaly G. HPLC glycosaminoglycan analysis in patients with Graves' disease. Clin Sci 1997; 92: 511-517
115. Channick BJ, Adlin EV, Marks AD, et al. Hyperthyroidism and mitral-valve prolapse. N Engl J Med 1981; 305: 497-500
116. Marks AD, Channick BJ, Adlin EV, et al. Chronic thyroiditis and mitral valve prolapse. Ann Intern Med 1985; 102: 479-483
117. Kahaly G. Graves' disease and mitral valve prolapse. JAMA 1987; 257: 22
118. Kahaly G, Erbel R, Mohr-Kahaly S, et al. Morbus Basedow und Mitralklappenprolaps. Dtsch Med Wschr 1987; 112: 248-253
119. Kahaly G, Mohr-Kahaly S, Beyer J, Meyer J. 1995 Prevalence of myxomatous mitral valve prolapse in patients with lymphocytic thyroiditis. Am J Cardiol 76: 1309-1310
120. Malcolm AD. Mitral valve prolapse associated with other disorders. Casual coincidence, common link, or fundamental genetic disturbance? Br Heart J 1985; 53: 353-362
121. Nishimura RA, McGoon MD, Schuub C, et al. Echocardiographically documented mitral-valve prolapse. Long-term follow-up of 237 patients. N Engl J Med 1985; 313: 1305-1309
122. Marks AR, Choong CY, Sanfilippo AJ, Ferre M, Weyman AE. Identification of high-risk and low-risk subgroups of patients with mitral-valve prolapse. N Engl J Med 1989; 320: 1031-1036
123. Wiersinga WM. Amiodarone and the Thyroid. In Weetman AP, Grossman A (Eds): Pharmacotherapeutics of the thyroid gland, Handb. Exp. Pharm. 128, Springer-Verlag, Berlin, 1997, pp 225-287
124. Trip MD, Wiersinga WM, Plomp TA. Incidence, predictability, and pathogenesis of amiodarone-induced thyrotoxicosis and hypothyroidism. Am J Med 1991; 91: 507-511
125. Wiersinga WM, Trip MD. Amiodarone and thyroid hormone metabolism. Postgrad Med J 1986; 62: 909-914
126. Gøtzsche LBH, Orskov H. Cardiac triiodothyronine nuclear receptor binding capacities in amiodarone treated, hypo- and hyperthyroid rats. Eur J Endocrinol 1994; 130: 281-290
127. Hartong R, Wiersinga WM, Plomp TA. Amiodarone reduces the effects of T3 on beta-adrenergic receptor density in rat heart. Horm Metab Res 1990; 22: 85- 89
128. Bagchi N, Brown TR, Schneider DS, Banerjee SK. Effect of amiodarone on rat heart myosin isoenzymes. Circ Res 1987; 60: 621-625
129. Franklyn JA, Green NK, Gammage MD, Ahlquist JAO, Sheppard MC. Regulation of a- and ß-myosin heavy chain messenger RNAs in the rat myocardium by amiodarone and by thyroid status. Clin Sci 1989; 76: 463-467
130. Gøtzsche LBH. Acute increase in cardiac performance after triiodothyronine blunted response in amiodarone -treated pigs. J Cardiovasc Pharmacol 1994; 23: 141-148
131. Gøtzsche LBH. ß-adrenergic receptors, voltage-operated Ca++ channels, nuclear triiodothyronine receptors and triiodothyronine concentration in pig myocardium after long-term low-dose amiodarone treatment. Acta Endocrinol 1993; 129: 337-347